뒤로
Genflow Biosciences PLC (GENFF) 수입
GENFF 주가 차트
GENFF 수입
Genflow Biosciences PLC
$0.03
0%
$0
종가: Mar 27, 16:00:00 GMT-4
$0.03
0%
$0
애프터마켓: Mar 27, 20:00:00 GMT-4
Earnings FAQ
GENFF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Genflow Biosciences PLC GENFF의 지난 분기 매출 실적은 어땠나요?
Genflow Biosciences PLC의 매출 추정치는 얼마인가요?
Genflow Biosciences PLC의 수익 품질 점수는 얼마인가요?
Genflow Biosciences PLC는 언제 수익을 보고하나요?
Genflow Biosciences PLC의 예상 수익은 얼마인가요?
Genflow Biosciences PLC은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.03
시가
$0.03
일일 범위
$0.03 - $0.03
52주 범위
$0.01 - $0.0645
거래량
30.0K
평균 거래량
8.9K
배당수익률
--
EPS(TTM)
-0.01
시가총액
$16.0M
Genflow Biosciences Plc란 무엇인가요?
Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.